<?xml version="1.0" encoding="UTF-8"?>
<p id="Par19">Emodin (
 <bold>3</bold>) is a naturally occurring anthraquinone derivative and an active ingredient of medicinal plants including 
 <italic>Rheum palmatum</italic> L., 
 <italic>Rheum tanguticum</italic> Maxim. ex Balf., 
 <italic>Polygonum cuspidatum</italic> Siebold &amp; Zucc., 
 <italic>Polygonum multiflorum</italic> Thunb., 
 <italic>Aloe vera</italic> (L.) Burm.f., 
 <italic>Senna obtusifolia</italic> (L.) H.S.Irwin &amp; Barneby (Dong et al. 
 <xref ref-type="bibr" rid="CR28">2016</xref>; Zhou et al., 
 <xref ref-type="bibr" rid="CR135">2020a</xref>, 
 <xref ref-type="bibr" rid="CR137">b</xref>), and 
 <italic>Cassia tora</italic> L. Emodin inhibited SARS-CoV via the blockage of viral entry by binding to the spike proteins and interfering with SARS-CoV 3CL
 <sup>pro</sup> activity (Hyun et al. 
 <xref ref-type="bibr" rid="CR45">2009</xref>). In assays involving SARS-CoV and HCoV-OC43, emodin in a dose-dependent manner significantly blocked the interaction between the SARS-CoV spike protein and ACE2 (a functional SARS-CoV receptor), inhibited the 3a ion channel (
 <italic>K</italic>
 <sub>1/2</sub> value of about 20 μM), and stopped new coronavirus release (Dong et al. 
 <xref ref-type="bibr" rid="CR28">2016</xref>; Ho et al. 
 <xref ref-type="bibr" rid="CR39">2007</xref>). SARS-CoV-2 spike protein directly binds to the host cell surface ACE2 receptor facilitating virus entry and replication (Zhang et al. 
 <xref ref-type="bibr" rid="CR127">2020</xref>). Corollary, emodin can be considered a potential lead therapeutic agent in the treatment of SARS-CoV-2 infection. Experimental data now suggest that combining emodin and the drug toremifene, a first-generation non-steroidal selective estrogen receptor modulator for the treatment of metastatic breast cancer, provides a potential therapeutic approach for SARS-CoV-2 (Zhou et al., 
 <xref ref-type="bibr" rid="CR135">2020a</xref>, 
 <xref ref-type="bibr" rid="CR137">b</xref>).
</p>
